Washington, D.C. — Federal investigators have found that nursing homes across the United States are deliberately misdiagnosing residents with schizophrenia — a condition most of them don’t have — to disguise the widespread, unauthorized use of powerful antipsychotic drugs.
The findings come from a pair of reports released in March by the Department of Health and Human Services Office of Inspector General, which reviewed 40 focused nursing home inspections carried out by the Centers for Medicare and Medicaid Services. The picture that emerged was deeply troubling: facilities routinely giving antipsychotic medications to residents with dementia as a way to control behavior — essentially using drugs as chemical restraints — while bypassing required safeguards designed to protect patients.
What makes the second report particularly striking is the deception involved. Some nursing homes aren’t just misusing the drugs — they’re gaming the system to hide it. By slapping a schizophrenia label on residents, facilities can sidestep restrictions on antipsychotic use that would otherwise apply. That false diagnosis also has a direct effect on public quality ratings, inflating a facility’s score on CMS’s Five-Star system.
“The inappropriate use of antipsychotic drugs in nursing homes has been a longstanding concern for Congress and others,” the OIG stated in its findings.
Not a New Problem — But Still No Fix
That’s perhaps the most frustrating part of this story. None of this is new. The FDA issued a black-box warning about antipsychotics in dementia patients back in 2005, after studies linked the drugs to elevated death rates. In 2011, OIG Inspector General Daniel Levinson called for public outrage and demanded solutions. A 2020 Congressional investigation revisited the same patterns. And a 2023 review found the same problems — without any meaningful financial penalties to show for it.
The current fine cap for false certifications runs between ,000 and ,000. Critics say that’s not a deterrent — it’s a rounding error for a facility making millions annually.
It’s part of a broader pattern of medication overreach in nursing homes. The industry has also come under pressure for unnecessary antibiotic prescribing that puts residents at risk — a problem that, like antipsychotic misuse, tends to reflect staffing shortcuts more than sound clinical judgment.
What CMS Is Being Asked to Do
The OIG’s recommendations are direct: CMS should strengthen oversight of antipsychotic prescribing, closely monitor facilities with abnormally high schizophrenia diagnosis rates, target high-risk nursing homes for follow-up inspections, and make sure residents and their families receive clear, plain-language information about any antipsychotic drugs being administered.
Whether CMS moves quickly on those recommendations is an open question. The agency has been operating with roughly 1,000 fewer employees than usual — hardly an ideal setup for a major new enforcement push.
For families with loved ones in nursing homes, the OIG reports serve as a reminder to ask direct questions: Is my family member on an antipsychotic? Was a schizophrenia diagnosis ever given — and if so, when and why? Have the required safeguards been documented and followed?
The answers to those questions may matter more than any star rating on a government website.
